JPWO2020027239A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020027239A5 JPWO2020027239A5 JP2020534728A JP2020534728A JPWO2020027239A5 JP WO2020027239 A5 JPWO2020027239 A5 JP WO2020027239A5 JP 2020534728 A JP2020534728 A JP 2020534728A JP 2020534728 A JP2020534728 A JP 2020534728A JP WO2020027239 A5 JPWO2020027239 A5 JP WO2020027239A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cancer
- amino acid
- group
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 54
- 210000004027 cell Anatomy 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 230000001939 inductive effect Effects 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 9
- 239000002157 polynucleotide Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 210000001808 exosome Anatomy 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 4
- 101000590482 Homo sapiens Kinetochore protein Nuf2 Proteins 0.000 claims description 3
- 102100032431 Kinetochore protein Nuf2 Human genes 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 13
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 13
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 235000001014 amino acid Nutrition 0.000 claims 5
- 230000008685 targeting Effects 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 3
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018145607 | 2018-08-02 | ||
| JP2018145607 | 2018-08-02 | ||
| PCT/JP2019/030117 WO2020027239A1 (ja) | 2018-08-02 | 2019-08-01 | Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020027239A1 JPWO2020027239A1 (ja) | 2021-08-10 |
| JPWO2020027239A5 true JPWO2020027239A5 (https=) | 2022-08-01 |
| JP7448124B2 JP7448124B2 (ja) | 2024-03-12 |
Family
ID=69232532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020534728A Active JP7448124B2 (ja) | 2018-08-02 | 2019-08-01 | Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20210371462A1 (https=) |
| EP (1) | EP3831943A4 (https=) |
| JP (1) | JP7448124B2 (https=) |
| KR (1) | KR20210040106A (https=) |
| CN (1) | CN112839950A (https=) |
| AU (1) | AU2019313948A1 (https=) |
| BR (1) | BR112021001664A2 (https=) |
| CA (1) | CA3108403A1 (https=) |
| IL (1) | IL280450A (https=) |
| MX (1) | MX2021001357A (https=) |
| SG (1) | SG11202101090RA (https=) |
| TW (1) | TW202023581A (https=) |
| WO (1) | WO2020027239A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111363009B (zh) * | 2020-03-18 | 2020-10-30 | 北京鼎成肽源生物技术有限公司 | 一种直肠癌靶标抗原及其刺激培养的ctl细胞及其应用 |
| CN118930633A (zh) * | 2023-05-12 | 2024-11-12 | 中国科学院深圳先进技术研究院 | 肿瘤相关抗原表位肽及其应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| JPS60217905A (ja) | 1984-04-13 | 1985-10-31 | のむら産業株式会社 | 自動包装機 |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| JP2000516090A (ja) | 1996-07-26 | 2000-12-05 | スローン―ケッタリング インスティチュート フォー キャンサー リサーチ | 遺伝子的免疫化のための方法と試薬 |
| US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| WO1999010378A1 (en) | 1997-08-25 | 1999-03-04 | Suntory Limited | Pompilid wasp-derived neuropeptides |
| JP4413429B2 (ja) | 1998-06-25 | 2010-02-10 | 株式会社グリーンペプタイド | サイクロフィリンｂ由来の腫瘍抗原ペプチド |
| US7157091B1 (en) | 1999-06-18 | 2007-01-02 | Ludwig Institute For Cancer Research | MAGE-A1 peptides presented by HLA class II molecules |
| US20030211510A1 (en) | 1999-06-30 | 2003-11-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030170255A1 (en) | 1999-06-30 | 2003-09-11 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6858204B2 (en) | 1999-06-30 | 2005-02-22 | Corxia Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| CA2384713A1 (en) | 1999-09-29 | 2001-04-05 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
| US7026443B1 (en) | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
| WO2002004514A2 (en) | 2000-07-11 | 2002-01-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| WO2002046416A2 (en) * | 2000-12-04 | 2002-06-13 | Argonex Pharmaceuticals | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7214786B2 (en) | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| DK2336167T3 (da) | 2001-03-14 | 2019-09-02 | Dako Denmark As | MHC-molekylkonstrukter og deres anvendelse til diagnose og terapi |
| US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| WO2003025010A2 (en) | 2001-09-17 | 2003-03-27 | Eirx Therapeutics Limited | Human delta-n p73 molecules and uses thereof |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| DE60327786D1 (de) | 2002-09-12 | 2009-07-09 | Oncotherapy Science Inc | Kdr-peptide und diese enthaltende impfstoffe |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| CA2500521A1 (en) | 2002-10-02 | 2004-09-23 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2005029067A2 (en) | 2003-09-24 | 2005-03-31 | Oncotherapy Science, Inc. | Method of diagnosing breast cancer |
| EP2336778A1 (en) | 2004-03-24 | 2011-06-22 | Oncotherapy Science, Inc. | Compositions and methods for treating lung cancer |
| WO2006031221A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| CN101175862A (zh) | 2005-02-10 | 2008-05-07 | 肿瘤疗法科学股份有限公司 | 诊断膀胱癌的方法 |
| EP2295570A1 (en) | 2005-07-27 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
| EP2311985A1 (en) | 2005-07-27 | 2011-04-20 | Oncotherapy Science, Inc. | Sirna for treating esophageal cancer |
| EP1915622A2 (en) | 2005-07-29 | 2008-04-30 | Oncotherapy Science, Inc. | Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex |
| JP5276846B2 (ja) | 2005-09-13 | 2013-08-28 | 国立大学法人三重大学 | Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞 |
| US7776341B2 (en) | 2006-08-10 | 2010-08-17 | Colorado State University Research Foundation | Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens |
| EP3620465B1 (en) | 2007-07-03 | 2025-02-19 | Dako Denmark A/S | Improved methods for generation, labeling and use of mhc multimers |
| PT2186889E (pt) | 2007-08-20 | 2015-06-17 | Oncotherapy Science Inc | Péptido cdca1 e agente farmacêutico que o compreende |
| TWI526219B (zh) | 2008-06-19 | 2016-03-21 | 腫瘤療法 科學股份有限公司 | Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗 |
| EP2337795A2 (en) | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| TWI469791B (zh) | 2009-02-18 | 2015-01-21 | Oncotherapy Science Inc | Ｆｏｘｍ１胜肽以及含此胜肽之疫苗 |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| EP2872532A4 (en) * | 2012-07-10 | 2016-04-13 | Oncotherapy Science Inc | CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH |
| EP3981416B1 (en) * | 2014-08-04 | 2024-03-20 | OncoTherapy Science, Inc. | Koc1-derived peptide and vaccine including same |
| JP6700512B2 (ja) | 2014-08-04 | 2020-05-27 | オンコセラピー・サイエンス株式会社 | Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン |
| CA2994929A1 (en) * | 2015-08-12 | 2017-02-16 | Oncotherapy Science, Inc. | Depdc1-derived peptide and vaccine containing same |
| BR112018005581A2 (pt) | 2015-10-08 | 2018-10-16 | Oncotherapy Science, Inc. | peptídeo derivado de foxm1 e vacina incluindo o mesmo |
-
2019
- 2019-07-31 TW TW108127154A patent/TW202023581A/zh unknown
- 2019-08-01 WO PCT/JP2019/030117 patent/WO2020027239A1/ja not_active Ceased
- 2019-08-01 MX MX2021001357A patent/MX2021001357A/es unknown
- 2019-08-01 AU AU2019313948A patent/AU2019313948A1/en not_active Withdrawn
- 2019-08-01 US US17/264,277 patent/US20210371462A1/en not_active Abandoned
- 2019-08-01 BR BR112021001664-3A patent/BR112021001664A2/pt not_active Application Discontinuation
- 2019-08-01 KR KR1020217006095A patent/KR20210040106A/ko not_active Withdrawn
- 2019-08-01 EP EP19844090.1A patent/EP3831943A4/en active Pending
- 2019-08-01 CA CA3108403A patent/CA3108403A1/en active Pending
- 2019-08-01 SG SG11202101090RA patent/SG11202101090RA/en unknown
- 2019-08-01 JP JP2020534728A patent/JP7448124B2/ja active Active
- 2019-08-01 CN CN201980064092.0A patent/CN112839950A/zh active Pending
-
2021
- 2021-01-27 IL IL280450A patent/IL280450A/en unknown
-
2023
- 2023-01-06 US US18/094,167 patent/US12195559B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5393144B2 (ja) | Ｈｌａ−ａ＊３３０３拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物 | |
| JP5921494B2 (ja) | 癌ワクチン組成物 | |
| ES2658842T3 (es) | Péptidos de epítope de CDCA1 y vacunas que los contiene | |
| JP6675987B2 (ja) | 腫瘍抗原ペプチド | |
| CN106243213B (zh) | 一种肿瘤相关抗原XAGE-1b短肽及应用 | |
| JP6423889B2 (ja) | Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 | |
| JPWO2020027239A5 (https=) | ||
| CN106279392A (zh) | 肿瘤相关抗原XAGE‑1b短肽及其应用 | |
| RU2022100330A (ru) | Пептид, полученный из depdc1, и содержащая его вакцина | |
| JPWO2022149549A5 (https=) | ||
| JP2021043204A (ja) | 免疫に基づく療法のための、免疫原性ｍｈｃクラスｉｉペプチドの同定 | |
| CN105531368A (zh) | 肿瘤抗原肽 | |
| JPWO2022071435A5 (https=) | ||
| CN106279391B (zh) | 肿瘤相关抗原XAGE-1b短肽及应用 | |
| RU2021105058A (ru) | Пептид, полученный из cdca1, и содержащая его вакцина | |
| CN110016073A (zh) | 一种XAGE-1b九肽及其应用 | |
| JP2008260689A (ja) | Ｈｌａ−ａ２４分子結合性副甲状腺ホルモン関連蛋白由来ペプチドを含有する医薬組成物 | |
| HK1125968B (en) | Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same |